CN110172420B - 一株鼠李糖乳杆菌及其应用 - Google Patents
一株鼠李糖乳杆菌及其应用 Download PDFInfo
- Publication number
- CN110172420B CN110172420B CN201910404538.1A CN201910404538A CN110172420B CN 110172420 B CN110172420 B CN 110172420B CN 201910404538 A CN201910404538 A CN 201910404538A CN 110172420 B CN110172420 B CN 110172420B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- strain
- cfu
- planting
- candida albicans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 103
- 230000004083 survival effect Effects 0.000 claims abstract description 34
- 241000607265 Vibrio vulnificus Species 0.000 claims abstract description 26
- 241000222122 Candida albicans Species 0.000 claims abstract description 23
- 229940095731 candida albicans Drugs 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 26
- 241000719836 Anoectochilus formosanus Species 0.000 claims description 16
- 238000004321 preservation Methods 0.000 claims description 4
- 230000012010 growth Effects 0.000 abstract description 23
- 235000013618 yogurt Nutrition 0.000 abstract description 18
- 241000252212 Danio rerio Species 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 13
- 241000934230 Anoectochilus roxburghii Species 0.000 abstract description 10
- 244000052616 bacterial pathogen Species 0.000 abstract description 10
- 230000008021 deposition Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 7
- 229930182566 Gentamicin Natural products 0.000 description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 6
- 108010040201 Polymyxins Proteins 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 229960002518 gentamicin Drugs 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001098657 Pterois Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 4
- -1 N-acetyl-glucosidase Proteins 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000003415 peat Substances 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000031729 Bacteremia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001937 non-anti-biotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- AYRXSINWFIIFAE-UDKQPYHCSA-N (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound OC[C@H]1O[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-UDKQPYHCSA-N 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N D-Cellobiose Natural products OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 2
- 206010048685 Oral infection Diseases 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 2
- 229940089837 amygdalin Drugs 0.000 description 2
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 108010047754 beta-Glucosidase Proteins 0.000 description 2
- 102000006995 beta-Glucosidase Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000014048 cultured milk product Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- 229940093496 esculin Drugs 0.000 description 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960002160 maltose Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 2
- DLRVVLDZNNYCBX-ABXHMFFYSA-N melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-ABXHMFFYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 2
- 229940120668 salicin Drugs 0.000 description 2
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N Carbendazim Natural products C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 239000005747 Chlorothalonil Substances 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000005794 Hymexazol Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000005842 Thiophanate-methyl Substances 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000443 biocontrol Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000006013 carbendazim Substances 0.000 description 1
- JNPZQRQPIHJYNM-UHFFFAOYSA-N carbendazim Chemical compound C1=C[CH]C2=NC(NC(=O)OC)=NC2=C1 JNPZQRQPIHJYNM-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QGHREAKMXXNCOA-UHFFFAOYSA-N thiophanate-methyl Chemical group COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC QGHREAKMXXNCOA-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G24/00—Growth substrates; Culture media; Apparatus or methods therefor
- A01G24/20—Growth substrates; Culture media; Apparatus or methods therefor based on or containing natural organic material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一株鼠李糖乳杆菌,所述菌株保藏名称为鼠李糖乳杆菌B156,于2018年9月10日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为:CGMCC No.16453。本发明还公开了该鼠李糖乳杆菌在制备抑制白色念珠菌药物和抑制创伤弧菌药物、保健食品或普通食品中的应用,以及在制备延长金线莲组培苗套袋种植存活期制剂中的应用。本发明提供的鼠李糖乳杆菌B156以及利用该菌株制备的发酵酸奶能够显著抑制致病菌白色念珠菌的生长;该菌株能够显著提高斑马鱼被创伤弧菌攻毒后的存活率,并显著延长金线莲组培苗套袋种植存活期。因此,本发明提供的鼠李糖乳杆菌B156具有较高的社会应用价值。
Description
技术领域
本发明涉及微生物菌株及其应用技术领域,具体涉及一株鼠李糖乳杆菌及其应用。
背景技术
白色念珠菌(Candida albicans)是引起免疫低下宿主感染的重要条件致病真菌。尽管有抗真菌药物的治疗,目前真菌菌血症的病死率仍高,特别是念珠菌菌血症的病死率高达40%-80%。白色念珠菌繁殖会引起念珠菌感染,如阴道炎,龟头炎等。创伤弧菌(Vibrio vulnificus),或称为海洋弧菌,是一种栖息于海洋中的细菌。创伤弧菌广泛分布在海水中,创伤弧菌可从牡蛎等海产品中分离得到。该菌主要通过伤口接触海水造成感染,也可经口感染。经伤口感染时可导致蜂窝织炎及骨髓炎等多种炎症,经口感染时常迅速导致菌血症或败血症。感染本菌后如不及时治疗,病死率很高。目前,对于白色念珠菌和创伤弧菌的感染主要还是采用抗生素进行治疗,但是抗生素存在耐药性的问题,因此,开发能够有效抑制这些致病菌生长的非抗生素类产品具有重要意义。
金线莲为珍稀名贵中药材,来源于兰科 Orchidaceae 开唇兰属 Anoectochilus,其性平,味甘,具有清热凉血、除湿解毒等功效。近年来随着金线莲在医药、保健、美容及饮用品等诸多领域的广泛应用,国内外市场对金线莲需求量不断上升,市场缺口逐年加大,人工种植的规模迅速扩大。金线莲基原植物在生长发育过程对环境因子要求严格,而套袋式栽培模式能够使植株与外界隔离进而使得病菌和害虫相对不易侵入,于是套袋式栽培日渐成为金线莲种植行业倍受青睐的一种栽培模式。然而在金线莲的密封装袋种植过程中,由于空气湿度过大和通风透气效果不畅等问题,植株易受到茎腐病等病虫害的侵染,植株发病时病势发展迅速,危害严重时死亡率高达90%以上。目前,种植生产上对上述病害仍以化学防治为主,常用的抗病药物有甲霜-恶霉灵、多菌灵、百菌清和甲基托布津等杀菌剂,但是由于连续多年使用这些药剂产生的耐药性,使得防治效果逐年降低。因此,如能开发抑制茎腐病等致病菌生长的非抗生素类产品,有效延长金线莲组培苗的套袋种植存活期,对金线莲人工种植发展有积极的推动意义。
鼠李糖乳杆菌(Lactobacillus rhamnosus)是我国批准的可用于普通食品的菌种之一。目前,鼠李糖乳杆菌的益生功能及其在发酵食品中的应用已受到食品科学领域学者的高度重视。大量研究显示,鼠李糖乳杆菌肠道黏着率高,定植能力强,并具有高效降胆固醇,预防和治疗腹泻、排除毒素、预防龋齿、提高机体免疫力及抗癌等重要的生理保健功能。然而到目前为止,行业内未见将鼠李糖乳杆菌开发用于抑制特定致病菌(创伤弧菌)的药物、保健食品或普通食品的相关报道,也未见将鼠李糖乳杆菌开发用于延长金线莲组培苗套袋种植存活期的相关报道。
发明内容
本发明的目的是提供一株鼠李糖乳杆菌及其应用,开发了一株能够显著延长金线组培苗的套袋种植存活期,并对白色念珠菌、创伤弧菌抑制能力较强的菌株。
本发明的目的是通过以下技术方案实现的:一株鼠李糖乳杆菌,所述菌株保藏名称为鼠李糖乳杆菌(Lactobacillus rhamnosus)B156,于2018年9月10日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为:CGMCC No.16453。保藏单位地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编:100101。
本发明提供的鼠李糖乳杆菌B156分离自益生元处理的人体粪便,菌落特征为:在MRS平板培养基上培养24~48 h后,菌落呈圆形,乳白色,凸起,不透明,菌体呈杆状,大小为0.6~0.9 × 1.0~3.0 μm;适合生长的pH值为4.5~9.0,最适生长pH为7.0,适合生长的温度为30~40℃,最适生长温度33℃;能够利用的糖类包括:L-鼠李糖、L-阿拉伯糖、核糖、D-葡萄糖、D-甘露糖、D-果糖、D-半乳糖、甘露醇、山梨醇、N-乙酰葡萄糖胺、苦杏仁苷、熊果苷、七叶苷、水杨苷(柳醇)、D-纤维二糖、D-麦芽糖、D-乳糖、D-密二糖、D-蔗糖、海藻糖、D-松三糖D-龙胆二糖和D-松二糖;能够分泌白氨酸芳胺酶、缬氨酸芳胺酶、胱氨酸芳胺酶、β-葡萄糖苷酶、N-乙酰-葡萄糖胺酶、碱性磷酸酶、酸性磷酸酶、萘酚-AS-BI-磷酸水解酶、β-半乳糖苷酶和α-葡萄糖苷酶。该菌株及其发酵酸奶对致病菌白色念珠菌的生长具有非常显著的抑制作用;该菌株能够明显提高斑马鱼被创伤弧菌攻毒后的存活率,还能够显著延长金线组培苗套袋种植存活期。
本发明所述的鼠李糖乳杆菌在制备抑制白色念珠菌药物、保健食品或普通食品中的应用;所述药物、保健食品或普通食品中所含鼠李糖乳杆菌B156的活菌数为1.0×106-5.0×1011 cfu/mL或1.0×106-5.0×1011 cfu/g;优选活菌数为6.0×108 cfu/mL或6.0×108 cfu/g。
本发明所述的鼠李糖乳杆菌在制备抑制创伤弧菌药物、保健食品或普通食品中的应用;所述药物、保健食品或普通食品中所含鼠李糖乳杆菌B156的活菌数为1.0×106-5.0×1011cfu/mL或1.0×106-5.0×1011cfu/g,优选活菌数为2.0×106-2.0×108cfu/mL或2.0×106-2.0×108cfu/g,最优选活菌数为2.0×107 cfu/mL或2.0×107 cfu/g。
本发明所述的鼠李糖乳杆菌在制备能够延长金线组培苗套袋种植存活期的生防菌制剂中的应用,具体是将所述鼠李糖乳杆菌B156添加到栽培金线莲组培苗的栽培基质中,所述基质中所含鼠李糖乳杆菌B156的活菌数为1.0×106-5.0×1011 cfu/mL或1.0×106-5.0×1011 cfu/g,优选活菌数为活菌数为1.9×108-4.8×109 cfu/mL或1.9×108-4.8×109 cfu/g,最优选活菌数4.8×109 cfu/mL或4.8×109 cfu/g。
本发明提供的鼠李糖乳杆菌B156分离自人类肠道,该菌株以及利用该菌株制备的发酵乳制品对白色念珠菌的生长有非常优异的抑制效果,其抑制作用显著优于现有同类型的商业菌株和部分抗生素(多粘菌素、链霉素和庆大霉素);该菌株能够显著提高斑马鱼被创伤弧菌攻毒后的存活率,其作用明显优于现有同类型的商业菌株;该菌株还能够显著延长金线莲组培苗的套袋种植存活期,为金线莲人工套袋种植提供了非抗生素的抗病制剂。因此,本发明提供的鼠李糖乳杆菌B156具有较高的社会应用价值。
附图说明
图1为鼠李糖乳杆菌B156的菌落形态。
图2为鼠李糖乳杆菌B156的扫描电镜图。
图3为鼠李糖乳杆菌B156在不同温度下的生长曲线。
图4为鼠李糖乳杆菌B156在不同pH值下的生长曲线。
具体实施方式
以下的实施例便于更好地理解本发明,但并不限定本发明。下述实施例中的实验方法,若未特别指明,实施例中的培养基及实验条件均为常规培养基和实验条件。实施例中所用的试验材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1 鼠李糖乳杆菌(Lactobacillus rhamnosus)B156的分离与鉴定
1、菌株分离
从健康人体粪便体外发酵益生元(低聚木糖)的培养液中取0.1 mL培养液,分配到MRS液体培养基中,在37℃下恒温厌氧培养,直至菌落出现,用接种针挑取边缘生长良好的细菌,接种于新的MRS平板培养基上,待新接种的菌长成菌落后,再挑取其边缘的内生菌划线培养,如此反复得到纯化,直到得到单菌落,命名其为菌株B156。
其中MRS液体培养基配方为:胰蛋白胨10.0 g/L、牛肉粉5.0 g/L、酵母粉4.0 g/L、葡萄糖20.0 g/L、吐温80 1.0 mL/L、K2HPO4•3H2O 1.5 g/L、无水乙酸钠3.0 g/L、柠檬酸铵2.0 g/L、MgSO4•7H2O 0.2 g/L、MnSO4•H2O 0.04 g/L。pH值为6.0,在121℃灭菌20 min。
2、菌株鉴定
(1)菌落及菌体的形态观察:将菌株B156在MRS平板培养基上进行划线培养,在37℃恒温厌氧培养24~48 h后,菌落呈乳白色,凸起,不透明,菌落形态见图1。在扫描电子显微镜下观察,菌体呈杆状,大小为0.6~0.9 × 1.0~3.0 μm,其扫描电镜图为图2。
(2)菌株B156的生长特征观察:将菌株B156按体积比3.0%的接种量分别接种于MRS液体培养基中,置于不同温度下厌氧培养24 h,发现菌株在10℃或50℃下基本不能生长,在30℃~40℃环境下生长良好,最适生长温度为33℃(见图3);置于不同初始pH值环境下厌氧培养24 h,发现菌株在pH值范围为3.0~11.0的环境中菌株能够生长,且在pH值为5.0~8.0的环境中生长最快,最适生长pH值为7.0(见图4)。
(3)菌株B156的分子生物学鉴定:采用细菌全基因组快速抽提试剂盒,提取菌株B156的全基因组,通过选用细菌16S rDNA通用引物27F和1492R进行PCR,然后测序分析。测序结果经BLAST比对,鉴定该菌株为鼠李糖乳杆菌,基因序列如SEQ ID NO : 1所示,命名为:鼠李糖乳杆菌(Lactobacillus rhamnosus)B156,于2018年9月10日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为:CGMCC No.16453。保藏单位地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编:100101。
实施例2 鼠李糖乳杆菌(Lactobacillus rhamnosus)B156对糖类的利用性
应用API50CHL 试剂盒(Biomerieux,法国)检测实施例1中分离的菌株B156对糖类的利用性,结果显示:本发明鼠李糖乳杆菌B156能够利用L-鼠李糖、L-阿拉伯糖、核糖、D-葡萄糖、D-甘露糖、D-果糖、D-半乳糖、甘露醇、山梨醇、N-乙酰葡萄糖胺、苦杏仁苷、熊果苷、七叶苷、水杨苷(柳醇)、D-纤维二糖、D-麦芽糖、D-乳糖、D-密二糖、D-蔗糖、海藻糖、D-松三糖、D-龙胆二糖和D-松二糖。
实施例3 鼠李糖乳杆菌(Lactobacillus rhamnosus)B156的酶活性
应用APIZYM 试剂盒(Biomerieux,法国)检测实施例1 中分离的菌株B156的酶活性,结果显示:本发明鼠李糖乳杆菌B156能够分泌白氨酸芳胺酶、缬氨酸芳胺酶、胱氨酸芳胺酶、β-葡萄糖苷酶、N-乙酰-葡萄糖胺酶、碱性磷酸酶、酸性磷酸酶、萘酚-AS-BI-磷酸水解酶、β-半乳糖苷酶和α-葡萄糖苷酶。
实施例4 鼠李糖乳杆菌(Lactobacillus rhamnosus)B156发酵酸奶的制备
将实施例1中所述鼠李糖乳杆菌B156作为发酵菌株接种于液体乳培养基中,制备发酵乳制品。所述液体乳培养基配方为:每100 mL蒸馏水中添加奶粉12 g、白砂糖8 g。经100 ℃水浴加热30 min后,冷却至室温,置于超净工作台,吸取鼠李糖乳杆菌B156种子液(浓度为2.0×106 cfu/mL),接种体积比3.0%的接种量接种于上述液体乳培养基中,充分混匀,经33 ℃发酵12 h,得到鼠李糖乳杆菌B156发酵酸奶,测其活菌数约为1.0×108 cfu/mL。
实施例5 鼠李糖乳杆菌B156及其发酵酸奶对白色念珠菌生长的抑制试验
实验方法:以白色念珠菌为指示菌,将指示菌株(浓度约为:2.0×107 cfu/mL)分别涂布于LB琼脂平板上,用无菌打孔器在平板上打直径为6 mm的加样孔,每组设置3个重复;在孔中加入100 μL的实验组菌液及其对比组菌液或抗生素药片,于37℃生化培养箱中培养24 h。观察并记录抑菌圈大小。
实验组和对比组设计:
实验组1为浓度为6.0×108 cfu/mL的鼠李糖乳杆菌B156菌液;
实验组2为鼠李糖乳杆菌B156发酵酸奶组,即实施例4制备的酸奶,酸奶中的活菌数为1.0×108 cfu/mL;
对比组1为浓度为6.0×108 cfu/mL的鼠李糖乳杆菌ATCC 7469菌液;
对比组2为鼠李糖乳杆菌ATCC 7469发酵酸奶组,制备方法同实施例4所述,仅将B156替换为鼠李糖乳杆菌ATCC 7469,酸奶中的活菌数为1.0×108 cfu/mL;
对比组3为万古霉素组,30 μg/片,杭州微生物试剂有限公司生产;
对比组4为多粘菌素组,300 IU/片,杭州微生物试剂有限公司生产;
对比组5为链霉素组,10 μg/片,杭州微生物试剂有限公司生产;
对比组6为庆大霉素组,10 μg/片,杭州微生物试剂有限公司生产。
统计结果见表1。
表1 本发明鼠李糖乳杆菌B156和对比菌株以及抗生素对白色念珠菌生长的抑制活性
表1显示本发明鼠李糖乳杆菌B156及其发酵酸奶对白色念珠菌的生长具有很强的抑制作用。在同等条件下,与对比菌株鼠李糖乳杆菌ATCC 7469(对比组1)及其发酵酸奶(对比组2)相比,本发明的鼠李糖乳杆菌B156及其发酵酸奶对白色念珠菌的生长具有更为显著的抑制效果。
抗生素万古霉素组(对比组3)、多粘菌素(对比组4)、链霉素(对比组5)、庆大霉素(对比组6)对致病菌白色念珠菌的生长具有明显的抑制作用。对比本发明鼠李糖乳杆菌B156及其发酵酸奶,可以发现,本发明鼠李糖乳杆菌B156对致病菌白色念珠菌的抑菌效果与万古霉素相当,且明显优于多粘菌素、链霉素和庆大霉素,而本发明鼠李糖乳杆菌B156的发酵酸奶对致病菌白色念珠菌的抑菌效果也均优于多粘菌素、链霉素和庆大霉素。可以说,本发明鼠李糖乳杆菌B156及其发酵酸奶对致病菌白色念珠菌的这么优异的抑菌效果是完全没有预料到的。
实施例6 鼠李糖乳杆菌(Lactobacillus rhamnosus)B156对斑马鱼被创伤弧菌攻毒后存活率的影响
实验方法:98只斑马鱼随机分为7组,每组14只,每组单独饲养于1缸,将10 μL不同实验组和对比组的鼠李糖乳杆菌液添加于饲料中饲养斑马鱼,每天2次,连续饲养14天后,取10 μL创伤弧菌液(OD值为0.68的菌液稀释400倍)对每只斑马鱼进行注射攻毒,1天后,统计斑马鱼的存活情况,计算斑马鱼被创伤弧菌攻毒后的存活率,结果见表2。
空白对照组为不含鼠李糖乳杆菌的空白培养基;
实验组3为浓度为2.0×106 cfu/mL的鼠李糖乳杆菌B156菌液;
实验组4为浓度为2.0×107cfu/mL的鼠李糖乳杆菌B156菌液;
实验组5为浓度为2.0×108cfu/mL的鼠李糖乳杆菌B156菌液;
对比组7为浓度为2.0×106cfu/mL的鼠李糖乳杆菌ATCC 7469菌液;
对比组8为浓度为2.0×107cfu/mL的鼠李糖乳杆菌ATCC 7469菌液;
对比组9为浓度为2.0×108cfu/mL的鼠李糖乳杆菌ATCC 7469菌液。
表2 本发明鼠李糖乳杆菌B156对创伤弧菌攻毒的斑马鱼的存活率的影响
表2显示,斑马鱼被创伤弧菌攻毒后发生明显中毒现象,表现为鱼体死亡(空白对照组的斑马鱼被创伤弧菌攻毒后的存活率仅为7.14%),而本发明鼠李糖乳杆菌B156低、中、高浓度处理组(实验组3、4、5)的斑马鱼被创伤弧菌攻毒后的存活率分别为28.57%、64.28%和28.57%,均较空白对照组明显提高。尤其是经中浓度(2.0×107 cfu/mL)B156菌液饲养后的斑马鱼,其被创伤弧菌攻毒后的存活率比空白对照组高出57.14%。以上结果表明本发明鼠李糖乳杆菌B156能够显著降低创伤弧菌对斑马鱼的毒性,提高斑马鱼被创伤弧菌攻毒后的存活率。
对比菌株(鼠李糖乳杆菌ATCC 7469)低、中、高浓度处理组(对比组7、8、9)的斑马鱼被创伤弧菌攻毒后的存活率均为21.43%、35.17%和21.43%,均较空白对照组有所提高。但与同浓度的本发明鼠李糖乳杆菌B156相比,对比菌株(鼠李糖乳杆菌ATCC 7469)对斑马鱼被创伤弧菌攻毒后的存活率的改善效果明显更弱。
本发明实施例5和6中对比组中所用的鼠李糖乳杆菌ATCC 7469为模式菌株,购自美国模式菌种收集中心。
实施例7 鼠李糖乳杆菌(Lactobacillus rhamnosus)B156在金线莲组培苗套袋种植中的应用
将金线莲组培苗分别转移到7个不同处理组的土壤中进行套袋种植,每个处理组种植100株,每株单独套袋处理。7个不同组的土壤处理如下:
空白对照组:将泥炭土与沙子按重量比4:1充分混合,获得基础栽培基质;
实验组6(鼠李糖乳杆菌B156低浓度处理组):将B156菌粉溶于清水,拌入泥炭土中,然后与沙子按重量比4:1充分混合,获得含低浓度B156菌(活菌数:1.9×108 cfu/g)的栽培基质;
实验组7(鼠李糖乳杆菌B156菌中浓度处理组):将B156菌粉溶于清水,拌入泥炭土中,然后与沙子按重量比4:1充分混合,获得含中浓度B156菌(活菌数:9.6×108 cfu/g)的栽培基质;
实验组8(鼠李糖乳杆菌B156菌高浓度处理组):将B156菌粉溶于清水,拌入泥炭土中,然后与沙子按重量比4:1充分混合,获得含高浓度B156菌(活菌数:4.8×109 cfu/g)的栽培基质;
在套袋种植过程中,实时观察金线莲的存活期,存活期以存活率为90%时的第n天数计,存活率=存活株数/总株数×100%,记录结果如表3。
表3 不同处理组下金线莲组培苗套袋种植存活期
表3显示,空白对照组金线莲组培苗套袋种植存活期仅为20天,而实验组6、实验组7和实验组8的鼠李糖乳杆菌B156的金线莲组培苗套袋种植存活期较空白对照组均显著延长,其中最高可使金线莲组培苗套袋种植存活期可高达98天,比空白对照组延长了78天。以上结果表明,本发明提供的鼠李糖乳杆菌B156能够显著延长金线莲组培苗套袋种植存活期。
综上所述,本发明提供的鼠李糖乳杆菌B156及其发酵酸奶制品对致病菌白色念珠菌的生长具有明显的抑制作用,该菌株还能够显著提高斑马鱼被创伤弧菌攻毒后的存活率,并显著延长金线莲组培苗套袋种植存活期。同时,与现有同类型的模式菌株和抗生素(多粘菌素、链霉素和庆大霉素)相比,本发明提供的鼠李糖乳杆菌B156及其发酵酸奶对白色念珠菌生长的抑制活性明显更强。与现有同类型的模式菌株相比,本发明提供的鼠李糖乳杆菌B156对提高斑马鱼被创伤弧菌攻毒后的存活率效果明显更优;而且鉴于鼠李糖乳杆菌是我国批准的可用于普通食品的菌种之一,是属于行业内公认的安全性很高的菌株,所以本发明提供的鼠李糖乳杆菌B156具有很高的实际应用价值。
以上仅是本发明的若干个具体实施例。本发明不限于以上实施例,还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。
SEQUENCE LISTING
<110> 福建省农业科学院农业工程技术研究所
<120> 一株鼠李糖乳杆菌及其应用
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1433
<212> DNA
<213> 鼠李糖乳杆菌B156
<400> 1
tgcagtcgaa cgagttctga ttattgaaag gtgcttgcat cttgatttaa ttttgaacga 60
gtggcggacg ggtgagtaac acgtgggtaa cctgccctta agtgggggat aacatttgga 120
aacagatgct aataccgcat aaatccaaga accgcatggt tcttggctga aagatggcgt 180
aagctatcgc ttttggatgg acccgcggcg tattagctag ttggtgaggt aacggctcac 240
caaggcaatg atacgtagcc gaactgagag gttgatcggc cacattggga ctgagacacg 300
gcccaaactc ctacgggagg cagcagtagg gaatcttcca caatggacgc aagtctgatg 360
gagcaacgcc gcgtgagtga agaaggcttt cgggtcgtaa aactctgttg ttggagaaga 420
atggtcggca gagtaactgt tgtcggcgtg acggtatcca accagaaagc cacggctaac 480
tacgtgccag cagccgcggt aatacgtagg tggcaagcgt tatccggatt tattgggcgt 540
aaagcgagcg caggcggttt tttaagtctg atgtgaaagc cctcggctta accgaggaag 600
tgcatcggaa actggaaaac ttgagtgcag aagaggacag tggaactcca tgtgtagcgg 660
tgaaatgcgt agatatatgg aagaacacca gtggcgaagg cggctgtctg gtctgtaact 720
gacgctgagg ctcgaaagca tgggtagcga acaggattag ataccctggt agtccatgcc 780
gtaaacgatg aatgctaggt gttggagggt ttccgccctt cagtgccgca gctaacgcat 840
taagcattcc gcctggggag tacgaccgca aggttgaaac tcaaaggaat tgacgggggc 900
ccgcacaagc ggtggagcat gtggtttaat tcgaagcaac gcgaagaacc ttaccaggtc 960
ttgacatctt ttgatcacct gagagatcag gtttcccctt cgggggcaaa atgacaggtg 1020
gtgcatggtt gtcgtcagct cgtgtcgtga gatgttgggt taagtcccgc aacgagcgca 1080
acccttatga ctagttgcca gcatttagtt gggcactcta gtaagactgc cggtgacaaa 1140
ccggaggaag gtggggatga cgtcaaatca tcatgcccct tatgacctgg gctacacacg 1200
tgctacaatg gatggtacaa cgagttgcga gaccgcgagg tcaagctaat ctcttaaagc 1260
cattctcagt tcggactgta ggctgcaact cgcctacacg aagtcggaat cgctagtaat 1320
cgcggatcag cacgccgcgg tgaatacgtt cccgggcctt gtacacaccg cccgtcacac 1380
catgagagtt tgtaacaccc gaagccggtg gcgtaaccct ctaggagcga gcc 1433
Claims (6)
1.一株鼠李糖乳杆菌,其特征在于,所述菌株保藏名称为鼠李糖乳杆菌(Lactobacillus rhamnosus)B156,于2018年9月10日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为:CGMCC No .16453。
2.一种如权利要求1所述的鼠李糖乳杆菌在制备抑制白色念珠菌药物中的应用。
3.根据权利要求2所述的鼠李糖乳杆菌在制备抑制白色念珠菌药物中的应用,其特征在于,所述药物中所含鼠李糖乳杆菌B156的活菌数为1.0×106-5.0×1011 cfu/mL或1.0×106-5.0×1011 cfu/g。
4.一种如权利要求1所述的鼠李糖乳杆菌在制备抑制创伤弧菌药物中的应用。
5.根据权利要求4所述的鼠李糖乳杆菌在制备抑制创伤弧菌药物中的应用,其特征在于,所述药物中所含鼠李糖乳杆菌B156的活菌数为1.0×106-5.0×1011 cfu/mL或1.0×106-5.0×1011 cfu/g。
6.一种如权利要求1所述的鼠李糖乳杆菌在制备延长金线莲组培苗套袋种植存活期制剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910404538.1A CN110172420B (zh) | 2019-05-15 | 2019-05-15 | 一株鼠李糖乳杆菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910404538.1A CN110172420B (zh) | 2019-05-15 | 2019-05-15 | 一株鼠李糖乳杆菌及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110172420A CN110172420A (zh) | 2019-08-27 |
CN110172420B true CN110172420B (zh) | 2022-03-01 |
Family
ID=67691158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910404538.1A Active CN110172420B (zh) | 2019-05-15 | 2019-05-15 | 一株鼠李糖乳杆菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110172420B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112760247B (zh) * | 2020-11-10 | 2022-10-25 | 深圳华大生命科学研究院 | 用于预防和/或治疗生殖道菌群紊乱和/或骨质流失引起的疾病的鼠李糖乳杆菌 |
CN114381407B (zh) * | 2022-02-07 | 2024-05-31 | 金华银河生物科技有限公司 | 一种鼠李糖乳杆菌r7970及其产物和应用 |
CN117126788B (zh) * | 2023-10-24 | 2024-03-22 | 杭州微致生物科技有限公司 | 鼠李糖乳杆菌vb255及其应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009039549A2 (de) * | 2007-09-27 | 2009-04-02 | Herbert Wiesinger-Mayr | Verfahren zur bestimmung von mikroorganismen |
WO2017191093A1 (fr) * | 2016-05-02 | 2017-11-09 | Lacto Research Sprl | Procede d'enrobage de microorganismes, poudre desdits microorganismes enrobes et composition pharmaceutique, nutraceutique, cosmetique, alimentaire ou sanitaire la comprenant |
CN108004188A (zh) * | 2018-01-11 | 2018-05-08 | 广东龙创基药业有限公司 | 一种鼠李糖乳杆菌及其用于制备阴道抑菌药物的应用 |
CN108048347A (zh) * | 2017-12-06 | 2018-05-18 | 河北然生物科技有限公司 | 鼠李糖乳杆菌、鼠李糖乳杆菌制剂及其用途 |
CN108148789A (zh) * | 2018-03-06 | 2018-06-12 | 河南科技学院 | 一种鼠李糖乳杆菌及其在制备细菌素中的应用 |
DE102017113263A1 (de) * | 2017-06-16 | 2018-12-20 | Lactopia GmbH | Pharmazeutische Zusammensetzung enthaltend Bakterienstämme aus der Familie der Lactobacillaceae und Molke |
CN109136131A (zh) * | 2018-08-27 | 2019-01-04 | 南昌大学 | 一株具有缓解结肠炎功效的鼠李糖乳杆菌及其应用 |
CN109504637A (zh) * | 2018-12-29 | 2019-03-22 | 福建省农业科学院农业工程技术研究所 | 一株戊糖片球菌及其应用 |
CN111088298A (zh) * | 2020-01-09 | 2020-05-01 | 吴雨昌 | 一种利用益生菌发酵提高金线莲活性成分含量的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102834520B (zh) * | 2009-10-30 | 2016-05-25 | 生物基因创新有限责任公司 | 甲基磺酰甲烷(msm)用于调制微生物活性的用途 |
AU2018230495A1 (en) * | 2017-03-10 | 2019-10-03 | Biohm Health Llc | Compositions and methods for promoting a healthy microbial flora in a mammal |
-
2019
- 2019-05-15 CN CN201910404538.1A patent/CN110172420B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009039549A2 (de) * | 2007-09-27 | 2009-04-02 | Herbert Wiesinger-Mayr | Verfahren zur bestimmung von mikroorganismen |
WO2017191093A1 (fr) * | 2016-05-02 | 2017-11-09 | Lacto Research Sprl | Procede d'enrobage de microorganismes, poudre desdits microorganismes enrobes et composition pharmaceutique, nutraceutique, cosmetique, alimentaire ou sanitaire la comprenant |
DE102017113263A1 (de) * | 2017-06-16 | 2018-12-20 | Lactopia GmbH | Pharmazeutische Zusammensetzung enthaltend Bakterienstämme aus der Familie der Lactobacillaceae und Molke |
CN108048347A (zh) * | 2017-12-06 | 2018-05-18 | 河北然生物科技有限公司 | 鼠李糖乳杆菌、鼠李糖乳杆菌制剂及其用途 |
CN108004188A (zh) * | 2018-01-11 | 2018-05-08 | 广东龙创基药业有限公司 | 一种鼠李糖乳杆菌及其用于制备阴道抑菌药物的应用 |
CN108148789A (zh) * | 2018-03-06 | 2018-06-12 | 河南科技学院 | 一种鼠李糖乳杆菌及其在制备细菌素中的应用 |
CN109136131A (zh) * | 2018-08-27 | 2019-01-04 | 南昌大学 | 一株具有缓解结肠炎功效的鼠李糖乳杆菌及其应用 |
CN109504637A (zh) * | 2018-12-29 | 2019-03-22 | 福建省农业科学院农业工程技术研究所 | 一株戊糖片球菌及其应用 |
CN111088298A (zh) * | 2020-01-09 | 2020-05-01 | 吴雨昌 | 一种利用益生菌发酵提高金线莲活性成分含量的方法 |
Non-Patent Citations (2)
Title |
---|
"Dietary supplementation of Bacillus subtilis and fructooligosaccharide enhance the growth,non-specific immunity of juvenile ovate pompano,Trachinotus ovatus and its disease resistance against Vibrio vulnificus";Qin Zhang等;《Fish&Shellfish Immunology》;20140531;第38卷(第1期);第7-14页 * |
"鼠李糖乳杆菌产生抗菌物质的抑菌作用和特性研究";刘冬梅等;《中国乳品工业》;20060125(第1(2006)期);第13-16页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110172420A (zh) | 2019-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109504637B (zh) | 一株戊糖片球菌及其应用 | |
KR100587447B1 (ko) | 바실러스 서브틸리스 eb120 균주, 이를 포함하는 식물병 방제용 미생물 제제 및 이를 이용하여 식물병을 방제하는방법 | |
KR101569737B1 (ko) | 벼 근권에서 분리된 신규 식물 내생세균 바실러스 오리지콜라 및 이를 이용한 천연식물 보호 및 식물 강화제 개발 | |
CN110172420B (zh) | 一株鼠李糖乳杆菌及其应用 | |
JP2009511012A (ja) | バチルスサブチリスkccm10639またはkccm10640を含む植物病害防除用組成物およびこれらを用いた植物病害防除方法 | |
CN112522144B (zh) | 一种碰碰香内生贝莱斯芽孢杆菌及其应用 | |
CN111647518A (zh) | 一种贝莱斯芽孢杆菌微生物菌剂及制备方法 | |
CN110878270B (zh) | 一株副干酪乳杆菌副干酪亚种及其应用 | |
US20060018883A1 (en) | Microbial preparation & method for preventing and curing the bacterial wilt the plant and its use | |
CN114381403A (zh) | 一种贝莱斯芽孢杆菌loh112及其应用 | |
Al-Askar et al. | Antagonistic activity of an endemic isolate of Streptomyces tendae RDS16 against phytopathogenic fungi | |
KR101980805B1 (ko) | 락토바실러스 플란타룸 kjm2-5 균주 또는 이를 함유하는 흰점박이꽃무지 유충의 사료 조성물 | |
CN109652334A (zh) | 一种微生物复合菌剂及其制备方法和应用 | |
KR101922410B1 (ko) | 바실러스 오리지콜라 yc7011이 생산하는 식물 병해충 방제 효과를 나타내는 기주 저항성 유도 신규 물질 | |
JP2010284100A (ja) | ステビア発酵液の製造方法 | |
KR101139794B1 (ko) | 바실러스 서브틸리스 엠27과 5엠34의 혼합균주를 이용한 식물병 방제제 | |
KR20090058132A (ko) | 신규한 바실러스 섭틸리스 균주 및 이를 함유한 고추탄저병방제용 농약 제제 | |
KR100977530B1 (ko) | 스트렙토마이세스 sp. YD414 균주, 이를 포함하는식물병 방제제, 및 이를 이용한 식물병 방제방법 | |
CN113717900B (zh) | 一株发酵乳杆菌及其应用 | |
KR20050024873A (ko) | 항진균 및 항세균 물질을 생산하는 스트렙토마이세스 속 균주 | |
KR100371503B1 (ko) | 양식어류의 사료첨가제용 미생물 제제 및 그 제조방법 | |
KR20100116023A (ko) | 슈도모나스 제니큘라타 mh102 균주 및 이를 이용한 식물병 방제방법 | |
KR101905058B1 (ko) | 바실러스 아밀로리퀴파시엔스 ak―0 균주 및 이를 포함하는 인삼 뿌리썩음병원균 방제용 미생물 제제 | |
TWI614338B (zh) | 自泥漿分離之門多薩假單胞菌菌株及其用途 | |
JP2007153873A (ja) | 土壌病害防除剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 350003 No. 54, 247 North Road, Gulou District, Fujian, Fuzhou Patentee after: Fujian Academy of Agricultural Sciences Agricultural Product Processing Research Institute Address before: 350000 No. 54 North 247 Road, Fujian, Fuzhou Patentee before: INSTITUTE OF AGRICULTURAL ENGINEERING TECHNOLOGY, FUJIAN ACADEMY OF AGRICULTURAL SCIENCES |
|
CP03 | Change of name, title or address |